|
Variable
|
Univariate analysis
|
Multivariable analysis
|
|---|
|
HR (95% CI)
|
P
|
HR (95% CI)
|
P
|
|---|
|
NTRS Group
|
8.84 (6.43–12.16)
|
< 0.001***
|
2.90 (1.74–4.82)
|
< 0.001***
|
|
Age
|
4.94 (3.63–6.72)
|
< 0.001***
|
2.39 (1.66–3.45)
|
< 0.001***
|
|
Gender
|
0.92 (0.70–1.22)
|
0.58
|
/
|
/
|
|
Histology
|
1.94 (1.66–2.25)
|
< 0.001***
|
/
|
/
|
|
Grade
|
4.86 (3.85–6.13)
|
< 0.001***
|
1.99 (1.51–2.62)
|
< 0.001***
|
|
IDH.status
|
0.10 (0.07–0.13)
|
< 0.001***
|
0.48 (0.29–0.80)
|
< 0.01**
|
|
Chr.1p/19q.codeletion
|
0.24 (0.15–0.38)
|
< 0.001***
|
/
|
/
|
|
MGMT.promoter.status
|
0.29 (0.22–0.39)
|
< 0.001***
|
/
|
/
|
|
Chr.7.gain&Chr.10.loss
|
8.75 (6.34–12.07)
|
< 0.001***
|
/
|
/
|
|
Chr.19&20 gain
|
3.37 (2.06–5.51)
|
< 0.001***
|
0.56 (0.34–0.93)
|
< 0.05*
|
|
ATRX.status
|
0.44 (0.32–0.62)
|
< 0.001***
|
/
|
/
|
- NTRS (low and high); Gender (female and male); Histology (astrocytoma, oligodendroglioma, oligoastrocytoma and glioblastoma); Grade (II, III and IV); IDH status (wildtype and mutant); 1p/19q (non-codeletion and codeletion); MGMT promoter status (methylated and unmethylated); Chr.7.gain&Chr.10.loss (yes and no); Chr.19&20 gain (non-gain and gain); ATRX.status (wildtype and mutant)
- P < 0.05 (*), P < 0.01 (**) and P < 0.001 (***) is regarded as statistically significant
- HR hazard ratio, CI confidence interval
